S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:APTO

Aptose Biosciences (APTO) Stock Price, News & Analysis

$1.23
-0.04 (-3.07%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$1.23
$1.29
50-Day Range
$1.23
$2.06
52-Week Range
$1.20
$8.70
Volume
36,400 shs
Average Volume
89,259 shs
Market Capitalization
$19.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.80

Aptose Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,508.4% Upside
$19.80 Price Target
Short Interest
Healthy
0.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.31) to ($3.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.10 out of 5 stars

Medical Sector

767th out of 907 stocks

Biological Products, Except Diagnostic Industry

133rd out of 149 stocks

APTO stock logo

About Aptose Biosciences Stock (NASDAQ:APTO)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Stock Price History

APTO Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Recap: Aptose Biosciences Q4 Earnings
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Why Is Aptose Biosciences (APTO) Stock Down Today?
Aptose Biosciences Inc APTO
Aptose Biosciences: Q3 Earnings Insights
Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)
See More Headlines
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
4/21/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.80
High Stock Price Target
$38.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,508.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-51,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.19) per share

Miscellaneous

Free Float
14,220,000
Market Cap
$19.35 million
Optionable
No Data
Beta
1.29
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

APTO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price target for 2024?

5 equities research analysts have issued 12-month price objectives for Aptose Biosciences' stock. Their APTO share price targets range from $5.00 to $38.00. On average, they expect the company's stock price to reach $19.80 in the next year. This suggests a possible upside of 1,508.4% from the stock's current price.
View analysts price targets for APTO
or view top-rated stocks among Wall Street analysts.

How have APTO shares performed in 2024?

Aptose Biosciences' stock was trading at $2.54 at the beginning of 2024. Since then, APTO stock has decreased by 51.5% and is now trading at $1.2310.
View the best growth stocks for 2024 here
.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,600 shares, an increase of 70.5% from the March 15th total of 50,200 shares. Based on an average trading volume of 96,300 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the shares of the stock are sold short.
View Aptose Biosciences' Short Interest
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our APTO earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings data on Tuesday, March, 26th. The biotechnology company reported ($1.44) EPS for the quarter, beating analysts' consensus estimates of ($1.48) by $0.04.

When did Aptose Biosciences' stock split?

Aptose Biosciences's stock reverse split on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APTO) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners